Neurology · Ridgeland, MS
Neurology studies in Ridgeland, MS
7 recruiting studies have a site in Ridgeland.
7 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Ridgeland, MS + 111 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 4
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
Pfizer
- Location
- Ridgeland, MS + 16 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
An Open Label Study Assessing REN Treatment in Headache Management in Temporomandibular Disorders
Theranica
- Location
- Ridgeland, MS + 3 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Ridgeland, MS + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Ridgeland, MS + 25 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Ridgeland, MS + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Ridgeland, MS + 111 other US sites
- Eligibility basics
- Ages 18–75
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.